Clinical trials referenced in this document:
Documents that mention this clinical trial
1421-P: The Impact of Blood Pressure on Risk of Death Is Influenced by Prior Cardiovascular Disease in Patients with Type 2 Diabetes and a Recent Coronary Event
Hispanic representation in diabetes cardiovascular outcomes trials
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes
Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial
Funding for this research was provided by:
Fulbright Commission Sweden
The Swedish Heart Association
The Swedish Society of Medicine
Region Östergötland (LIO-905431)
Received: 23 July 2020
Accepted: 1 October 2020
First Online: 12 October 2020
Ethics approval and consent to participate
: The study was approved by the appropriate national and institutional regulatory and ethics boards and all patients provided written informed consent.
: Not applicable.
: MOW has served on advisory boards or lectured for MSD, Lilly, Novo Nordisk and Sanofi, and has organized a professional regional meeting sponsored by Lilly, Rubin Medical, Sanofi, Novartis and Novo Nordisk. BC has received consulting fees for Amgen, Biogen, Corvia, Myokardia, and Novartis. RD has received speaker fees from Sanofi, Astra Zeneca and Eli Lilly. HG holds the McMaster-Sanofi Population Health Institute Chair in Diabetes Research and Care and reports research grants from Eli Lilly, AstraZeneca, Merck, Novo Nordisk and Sanofi; honoraria for speaking from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Sanofi; and consulting fees from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, Janssen, Sanofi, and Kowa. LK has received speaker´s honorarium (personal fee) from AstraZeneca, Novartis and Boehringer, unrelated to this manuscript. EL has received institutional funding for research grant support from Sanofi and Akebia. APM has received personal fees from Bayer, Fresenius, Novartis for participating in study committees outside the present work. EW has received speaker fees from Orion Pharma, Novartis Healthcare, Boehringer-Ingelheim, Merck. MR has received research funding through Oregon Health & Science University: Eli Lilly, Novo Nordisk, AstraZeneca, and honoraria for consulting: Adocia, AstraZeneca, Eli Lilly, GlaxoSmithKline, Intercept, Novo Nordisk, Sanofi, Theracos. JCT has received research grants from Amarin, Astra-Zeneca, DalCor, Esperion, Ionis, RegenXBio, Sanofi and Servier; honoraria from DalCor, Sanofi and Servier; holds minor equity interest in DalCor; and is an author of a patent on pharmacogenomics-guided CETP inhibition. SDS has received research grants from Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, BMS, Celladon, Cytokinetics, Eidos, Gilead, GSK, Ionis, Lone Star Heart, Mesoblast, MyoKardia, NIH/NHLBI, Neurotronik, Novartis, Respicardia, Sanofi Pasteur, Theracos, and has consulted for Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, BMS, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, Gilead, GSK, Ironwood, Merck, Myokardia, Novartis, Roche, Takeda, Theracos, Quantum Genetics, Cardurion, AoBiome, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau. MAP receives research support from Novartis, serves as a consultant for AstraZeneca, Corvidia, DalCor, GlaxoSmithKline, Novartis, Novo Nordisk, Pharmascience and Sanofi, and has equity in DalCor.